THI Brummer, A Heikkinen. Pharmaceutical thrombosis prophylaxis, bleeding complications and thromboembolism in a national cohort of hysterectomy for benign disease.Hum[J].Reprod,2012,27(6):1628-1636.
[2]
Auer, Rebecca Ann C,MD, et al. Postoperative Venous Thromboembolism Predicts Survival in Cancer Patients[J]. Annals of Surgery,2012,255(5):963-970.
[3]
Francisco Robert. The potential benefits of low-molecular-weight heparins in cancer Robert [J].Journal of Hematology & Oncology,2010,3(3):1-12.
[4]
Subarna Thirugnanam, Ruxandra Pinto,et al. Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review[J]. Critical Care,2012,16(2):23-26.
[5]
M Byrne, JV Reynolds. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery[J]. Br J Cancer,2010,102(1): 73-79.
[6]
J Yang, N Paredes,AKC Chan. Antithrombotic therapy in children with venous thromboembolism [J]. Hamostaseologie,2009,29:80-87.
[7]
Whitworth, Jenny M, Schneider, Kellie E, et al. Double Prophylaxis for Deep Venous Thrombosis in Patients With Gynecologic Oncology Who Are Undergoing Laparotomy: Does Preoperative [J].Anticoagulation Matter,2011,21(6):1131-1134.
[8]
Benson babu. Cancer and clots: All cases of venous thromboembolism are not treated the same[J]. Cleveland clinic journal of medicine,2009,76(2):129-135.
[9]
Mark N. Levine. New Antithrombotic Drugs: Potential for Use in Oncology[J].JCO,2009,27(29):4912-4918.
